Peps
What is Linaclotide?
Linaclotide is an orally administered peptide medicine for defined constipation conditions. Its clinical outcomes concern bowel function and associated symptoms.
Biological role or research focus
Intestinal secretion in constipation care.
Age limits and dehydration warnings matter; it is not a general gut-healing peptide.
Role reference: MedlinePlus · Linaclotide ↗
Names you may encounter
Linzess
Search terms can include brands, combinations, or historical names. They are not automatic product equivalents.
- Class / identity
- Guanylate cyclase-C agonist
- Main research area
- Constipation-related bowel function
- Evidence featured
- Human randomized trial
- Source check
- October 4, 2026
Source: MedlinePlus · Linaclotide ↗
Molecular structure
Mechanism & research rationale
It activates guanylate cyclase-C in the intestine and promotes intestinal fluid movement and transit. This local bowel mechanism differs from a systemic tissue-repair claim.
Source: MedlinePlus · Linaclotide ↗
Clinical uses & product context
The medication reference covers IBS with constipation and specified constipation uses in adults and children. Eligibility and age limits vary by indication; the adult studies below are not a substitute for pediatric labeling.
Source: MedlinePlus · Linaclotide ↗
What does the evidence show?
Selected published evidence, with the population, findings, and limits kept together. These original summaries draw on publication abstracts; they are not a systematic review.
Human randomized trial · 2011
Chronic constipation trials
Two randomized trials of linaclotide for chronic constipation.
- Population / model
- 1,276 patients across two trials.
- Study design
- Twelve-week blinded comparisons of two linaclotide groups with placebo.
- Main finding
- The sustained complete-spontaneous-bowel-movement endpoint was met by roughly 16–21% of treated participants versus 3–6% with placebo across trials.
- Limits & context
- A responder had both sufficient bowel frequency and improvement from baseline over most study weeks. This is a defined constipation endpoint, not evidence of general intestinal “repair.”
Source: Two randomized trials of linaclotide for chronic constipation. ↗
Read the original paper for methods, adverse events, funding, and conflicts of interest. Publisher access may require a subscription.
Further reading · 4 additional publication links
Exact-name PubMed search checked 2026-10-04. These records have not been appraised. A name match can include related compounds, combinations, or other formulations; it does not establish safety or benefit.
Irritable bowel syndrome. ↗
Medicina clinica · 2022 Jan 21 · Journal Article, Review
American Gastroenterological Association-American College of Gastroenterology Clinical Practice Guideline: Pharmacological Management of Chronic Idiopathic Constipation. ↗
Gastroenterology · 2023 Jun · Practice Guideline, Journal Article
Read available full text ↗
Management of Chronic Constipation: A Comprehensive Review. ↗
Internal medicine (Tokyo, Japan) · 2025 Jan 1 · Journal Article, Review
Read available full text ↗
Linaclotide. ↗
· 2012 · Review
New editorial updates
New source discoveries
Links appear automatically. Unreviewed discoveries are not verified medical findings.
Safety & precautions
Key precautions
Diarrhea and dehydration are key concerns, and bowel obstruction is an important contraindication. Pediatric restrictions must be checked against the exact current indication.
Source: MedlinePlus · Linaclotide ↗
This is not a complete list of contraindications, interactions, or adverse effects. Medicine labels apply to specific products and indications; research-use listings are not interchangeable with approved medicines.
What are people discussing?
No editorial transcript note has been reviewed for this profile yet. Below are the matching video records available for exploration; title and caption matches are not verified claims.
Watch the source discussions
0 matching video records · 0 with captions indexed.
Across the full library, 30 caption files are indexed from 20,199 inventoried videos. Most transcripts remain unreviewed. Select a thumbnail or timestamp to watch inside PepsRadar. Thumbnail images load from YouTube.
No matching video has been identified in the current snapshot.
Sources & supplier listings
Listings are grouped by the vendor’s stated identity. Blends and modified derivatives are labeled separately. Inclusion is not a quality assessment or an endorsement.
We have not added a supplier for this profile. Missing products and coded listings are not filled with guesses.
Catalog checked 2026-10-04. Seller listings retain their stated intended use. Shops covered: BioLongevity Labs, BioLongevity Supplements, American Peptides, PSPeptides. This is not a market-wide comparison. Affiliate participation does not determine evidence or editorial coverage.
Questions worth asking
- Which indication and formulation does the source describe?
- Does the video make a broader claim than the source supports?
- Age limits and dehydration warnings matter; it is not a general gut-healing peptide.
- What adverse effects, uncertainty, and conflicts of interest does the original source report?
Frequently asked questions
Is it a general “gut-healing” peptide?
That is broader than the studied constipation endpoints. Symptom or bowel-frequency improvement does not prove every form of intestinal repair.
Source: MedlinePlus · Linaclotide ↗
What does “complete spontaneous bowel movement” mean?
It is a defined trial outcome involving a bowel movement without rescue medication and a sense of complete evacuation; the study sets the exact responder rule.
Source: Two randomized trials of linaclotide for chronic constipation. ↗
References & editorial record
Source notes checked 2026-10-04. Original PepsRadar summaries. Not reviewed by a medical professional. Topic grouping is editorial navigation, not a treatment recommendation. Video notes specify which excerpts were reviewed; no full transcripts are published.